[Featured Stock] Shaperon Inhibits Metastatic Cancer Growth by 93%... "Also Reduces Cancer Recurrence Risk"

Shaperon is showing strong performance. This is interpreted as being influenced by the news that preclinical research results significantly enhancing anticancer treatment effects have been published in an international professional journal.

As of 10:33 AM on the 16th, Shaperon was trading at 4,395 KRW, up 370 KRW (9.19%) from the previous trading day.

On the same day, Shaperon announced that it had published preclinical research results in the international professional journal Pharmaceutics, which significantly enhanced anticancer treatment effects by combining 'anticancer immunotherapy technology targeting cancer stem cells' with 'high-intensity focused ultrasound technology.' The research was jointly conducted by Shaperon and the research team from Seoul National University College of Medicine.

In this study, Shaperon developed a treatment strategy that enhances immune response by combining high-intensity focused ultrasound technology with an anticancer immune cell vaccine. This showed groundbreaking potential in treating metastatic tumors that are difficult to cure. This approach demonstrated a dual therapeutic effect by physically removing primary tumors using high-intensity focused ultrasound while modulating the tumor microenvironment and suppressing the growth of metastatic cancer through tumor-targeted immune vaccines. Notably, preclinical results showed a 93.9% inhibition of metastatic tumor growth in mouse tumor models and targeted cancer stem cell-specific antigens to reduce the likelihood of cancer recurrence.

This technology is based on the ‘DAMPs (Damage Associated Molecular Patterns)’ theory published by Seungyong Sung, CEO of Shaperon, in 2004 in Nature Reviews Immunology. Using high-intensity focused ultrasound can artificially increase the production of DAMPs in cancer tissues. DAMPs activate immune cells in the body, greatly enhancing cancer elimination capabilities, thereby enabling the detection and removal of even metastatic cancer cells.

Shaperon previously published results on anticancer immunotherapy technology targeting cancer stem cells in the international journal Biomedicine & Pharmacotherapy in July last year. The company explained that this recent study is the world’s first technology to combine high-intensity focused ultrasound technology with cancer stem cell-targeted immune cell therapy technology, and it is evaluated as presenting potential for next-generation anticancer treatment approaches.

A Shaperon representative said, “Cancer stem cells suppress anticancer immune responses, increasing resistance to immune checkpoint inhibitors, so efforts to effectively eliminate them are ongoing, but there are still very few commercialized cases. This study is significant in that it has advanced anticancer immunotherapy technology capable of efficiently targeting and eliminating cancer stem cell antigens.”

He added, “Recently, research on cancer treatment strategies differentiated from existing methods by combining high-intensity focused ultrasound with anticancer antibody therapeutics is actively underway. We expect that the nanobody anticancer therapeutics being developed by the company will be combined to bring superior cancer treatment technologies to market early.”